Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-264 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| VX-264 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VX-264 | DRUG | Allogeneic human stem cell-derived islets. |
Key Inclusion Criteria: Clinical history of T1D with greater than or equal to (\>=) 5 years duration Participant is on a stable diabetic treatment Consistent use of continuous glucose monitoring (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study Ke...
Top 10 of 19 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 6 | PHASE3 | Tirzepatide, Baricitinib, LY4057996, Insulin Lispro |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 5 | PHASE3 | Insulin icodec, Insulin aspart, NNC0194-0499, Semaglutide, NNC0497-0040 |
| Sanofi SA Sponsored ADR | SNY | 12 | PHASE3 | teplizumab/mL, Brivekimig, Frexalimab, Insulin |
| Vertex Pharmaceuticals Incorporated | VRTX | 3 | PHASE3 | VX-880, VX-017, VX-264 |
| vTv Therapeutics, Inc. Class A | VTVT | 2 | PHASE3 | Cadisegliatin |
| SAB Biotherapeutics, Inc. | SABS | 1 | PHASE2 | SAB-142 |
| MannKind Corporation | MNKD | 2 | PHASE2 | Technosphere Insulin |
| Creative Medical Technology Holdings, Inc. | CELZ | 1 | PHASE1 | CELZ-201 |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh | IMCR | 1 | PHASE1 | IMC-S118AI |
| Sana Biotechnology, Inc. | SANA | 1 | EARLY_PHASE1 | UP421 |
VX-264 is an investigational small molecule being developed for the treatment of Type 1 Diabetes. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities. The drug is being studied to evaluate its safety, tolerability, and efficacy in participants with this condition.
VX-264 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX. The company is conducting a Phase 1 clinical trial to assess the drug's safety, tolerability, and efficacy in participants with Type 1 Diabetes.
VX-264 is in Phase 1 clinical development. It is an investigational drug, meaning it is not yet approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is designed to evaluate the safety, tolerability, and efficacy of VX-264 in participants with Type 1 Diabetes.
VX-264 is being studied in a Phase 1 clinical trial with the identifier NCT05791201. This trial is titled 'A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes' and is currently active but not recruiting. The study has an enrollment of 7 participants and is being conducted in multiple countries including the United States, Canada, Germany, Italy, Netherlands, Switzerland, and the United Kingdom.
No, VX-264 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for the treatment of Type 1 Diabetes. The drug is being studied in a clinical trial to evaluate its safety, tolerability, and efficacy, but it has not yet received regulatory approval for commercial use.